DE2527579A1 - Neue pharmazeutische zusammensetzungen - Google Patents
Neue pharmazeutische zusammensetzungenInfo
- Publication number
- DE2527579A1 DE2527579A1 DE19752527579 DE2527579A DE2527579A1 DE 2527579 A1 DE2527579 A1 DE 2527579A1 DE 19752527579 DE19752527579 DE 19752527579 DE 2527579 A DE2527579 A DE 2527579A DE 2527579 A1 DE2527579 A1 DE 2527579A1
- Authority
- DE
- Germany
- Prior art keywords
- dione
- dichlorophenyl
- pharmaceutical compositions
- dimethyloxazolidine
- new pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229940126601 medicinal product Drugs 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 241000700159 Rattus Species 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000001625 seminal vesicle Anatomy 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 201000010653 vesiculitis Diseases 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000002280 anti-androgenic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229960001712 testosterone propionate Drugs 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- -1 3- (3 ', 4'-dichlorophenyl) -5,5-dimethyloxazolidine- Chemical compound 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229960004279 formaldehyde Drugs 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7421603A FR2275206A1 (fr) | 1974-06-21 | 1974-06-21 | Application d'une oxazolidinedione a titre de medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2527579A1 true DE2527579A1 (de) | 1976-01-08 |
Family
ID=9140360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752527579 Withdrawn DE2527579A1 (de) | 1974-06-21 | 1975-06-20 | Neue pharmazeutische zusammensetzungen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4000291A (https=) |
| BE (1) | BE830474A (https=) |
| CA (1) | CA1038762A (https=) |
| DE (1) | DE2527579A1 (https=) |
| FR (1) | FR2275206A1 (https=) |
| GB (1) | GB1461897A (https=) |
| NL (1) | NL7507370A (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987002357A1 (fr) * | 1985-10-11 | 1987-04-23 | Sagami Chemical Research Center | Derives d'oxazolidinedione, procede de preparation et herbicides les contenant |
| FR2751965B1 (fr) * | 1996-08-01 | 1998-11-27 | Oreal | Nouveaux composes de la famille des aryl-2,4-dioxo-oxazolidines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909467A (en) * | 1958-07-09 | 1959-10-20 | Us Vitamin Pharm Corp | 3-(d-alpha-methylphenethyl)-5-methyl-1, 3-oxazolidine-2, 4-dione |
| CA926407A (en) * | 1967-12-01 | 1973-05-15 | Horiuchi Fukashi | 3-(3,4-dichlorophenyl) oxazolidine-2,4-dione derivatives |
| GB1250538A (https=) * | 1969-03-18 | 1971-10-20 |
-
1974
- 1974-06-21 FR FR7421603A patent/FR2275206A1/fr active Granted
-
1975
- 1975-06-10 US US05/585,718 patent/US4000291A/en not_active Expired - Lifetime
- 1975-06-17 CA CA229,564A patent/CA1038762A/en not_active Expired
- 1975-06-20 BE BE157536A patent/BE830474A/xx unknown
- 1975-06-20 DE DE19752527579 patent/DE2527579A1/de not_active Withdrawn
- 1975-06-20 NL NL7507370A patent/NL7507370A/xx not_active Application Discontinuation
- 1975-06-23 GB GB2651475A patent/GB1461897A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| BE830474A (fr) | 1975-12-22 |
| CA1038762A (en) | 1978-09-19 |
| US4000291A (en) | 1976-12-28 |
| FR2275206B1 (https=) | 1978-07-21 |
| GB1461897A (en) | 1977-01-19 |
| NL7507370A (nl) | 1975-12-23 |
| FR2275206A1 (fr) | 1976-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2649925C2 (de) | 5,5-Dimethyl-3-[4-nitro-3-(trifluormethyl)-phenyl]-2-imidazolidinone, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel | |
| DE3587321T2 (de) | Pharmazeutische zusammensetzungen mit gehalt an einer organo-germaniumverbindung und ihre anwendung. | |
| DE2015447B2 (de) | Muskelentspannendes Arzneimittel | |
| DE2527579A1 (de) | Neue pharmazeutische zusammensetzungen | |
| DE69115745T2 (de) | Verwendung von Steroidderivaten zur Behandlung der Endometriose | |
| Hoskins et al. | TTHE INHIBITION OF COMB GROWTH IN COCKERELS AND CAPONS BY ESTRONEW | |
| DE2557431A1 (de) | Topische antimikrobielle praeparate | |
| DE69125204T2 (de) | Therapeutische Anwendung von Histamin-H3-Agonisten, neue Wirkstoffe und Verwendung zur Herstellung von Arzneimitteln | |
| DE2504615B2 (de) | Verfahren zur herstellung eines geles mit einem gehalt an beta-methason- 17-benzoat bzw. fluocinolonacetonid und neomycin | |
| DE2728311A1 (de) | Ein piperazin-derivat und dessen salze enthaltende pharmazeutische zusammensetzungen | |
| DE3336292A1 (de) | Neue dichlorderivate der 16(alpha)-methylpregnanreihe, deren herstellung, deren verwendung als arzneimittel und die sie enthaltenden zusammensetzungen | |
| DE2508775C2 (de) | 3-oxo-17β-n-amyloxyöstra-4,9,11-trien, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zusammensetzung | |
| DE2937489A1 (de) | Arzneimittel zur behandlung hypertoner funktionszustaende der harnblase | |
| DE2646700C2 (https=) | ||
| DE2215499C2 (de) | Diäther des Östradiol | |
| DE69228112T2 (de) | Verfahren zur verbesserung des gedächtnisses und zur steigerung der lebensqualitet | |
| DE2221281C3 (de) | Pharmazeutische Zubereitungen mit entzündungshemmender und analgetischer Wirkung | |
| DE2615694A1 (de) | Pharmazeutische zusammensetzungen | |
| DE2059338C3 (de) | Verwendung von Cyproteronacetat bei der Behandlung der Pubertas praecox | |
| DE1960500B2 (de) | Verwendung eines extraktes aus urin von traechtigen stuten zur stabilisierung von synthetischem natriumoestronsulfat | |
| DE2011499A1 (de) | Arzneimittel aus Germaniumsäure und Cystein und Verfahren zu seiner Herstellung | |
| DE3333008C2 (https=) | ||
| DE69427927T2 (de) | Verwendung von Trimetazidin zur Herstellung von Medikamenten für die Behandlung von Gesundheitsstörungen, die durch die Nephrotoxizität von Cyclosporin A bedingt sind. | |
| DE2048547A1 (de) | Neue krampflosend wirkende pharma zeutische Mitte! | |
| DE3827953A1 (de) | Arzneimittelzubereitung aus einem extrakt der brennesselwurzel urtica kiovensis (rogowicz), dessen verwendung zur behandlung von geschwulsten und herstellverfahren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |